Development and validation of a LC-MS/MS method for assessment of an anti-inflammatory indolinone derivative by in vitro blood-brain barrier models

Journal of Pharmaceutical and Biomedical Analysis

Volumn 98, Issue , 2014, Pages 235-246

  Jähne, Evelyn A ^a   Eigenmann, Daniela E ^a   Culot, Maxime ^b   Cecchelli, Roméo ^b   Walter, Fruzsina R ^c   Deli, Mária A ^c   Tremmel, Robin ^d   Fricker, Gert ^d   Smiesko, Martin ^a   Hamburger, Matthias ^a   Oufir, Mouhssin ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITÉ D'ARTOIS   (France)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

(E,Z) 3 (4 Hydroxy 3,5 dimethoxybenzylidene)indolin 2 one; Anti inflammatory; Blood brain barrier (BBB); Isatis tinctoria; LC MS MS

Indexed keywords

3 (4 HYDROXY 3,5 DIMETHOXYBENZYLIDENE)INDOLIN 2 ONE; 3 (BENZYLIDENYL)INDOLIN 2 ONE; ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; MULTIDRUG RESISTANCE PROTEIN; UNCLASSIFIED DRUG; CALCEIN AM; FLUORESCEIN DERIVATIVE; INDOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CALCEIN-AM ASSAY; CATTLE; CLINICAL ASSESSMENT; COCULTURE; CONTROLLED STUDY; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; FREEZE THAWING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN INTERACTION; QUANTITATIVE STUDY; RAT; ROOM TEMPERATURE; TANDEM MASS SPECTROMETRY; VALIDATION STUDY; ANIMAL; BOVINAE; CELL CULTURE; CHEMISTRY; ENDOTHELIUM CELL; MALE; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; SWINE; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CATTLE; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FLUORESCEINS; HUMANS; INDOLES; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SWINE; TANDEM MASS SPECTROMETRY;

EID: 84902478877     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.05.026     Document Type: Article

References (51)

1. Kiefer S., Mertz A.C., Koryakina A., Hamburger M., Küenzi P. (E,Z)-3-(3',5'-dimethoxy-4'-hydroxy-benzylidene)-2-indolinone blocks mast cell degranulation. Eur. J. Pharm. Sci. 2010, 40:143-147.
2. Guideline on Bioanalytical Method Validation 21 July 2011, European Medicines Agency (EMEA/CHMP/EWP/192217/2009), London.
3. Guidance for Industry: Bioanalytical Method Validation May 2001, US Food and Drug Administration (FDA), Center for Drug Evaluation and Research.
4. Hamburger M. Isatis tinctoria - from the rediscovery of an ancient medicinal plant towards a novel anti-inflammatory phytopharmaceutical. Phytochem. Rev. 2002, 1:333-344.
5. Hurry J.B. The Woad Plant and its Dye 1973, AM Kelley.
6. Zhu Y.P. Chinese Materia Medica: Chemistry, Pharmacology, and Applications 1998, Harwood Academic Publishers, Amsterdam.
7. Recio M.C., Cerda-Nicolas M., Potterat O., Hamburger M., Rios L. Anti-inflammatory and antiallergic activity in vivo of lipophilic Isatis tinctoria extracts and tryptanthrin. Planta Med. 2006, 72:539-546.
8. Recio M.C., Cerda-Nicolas M., Hamburger M., Rios L. Anti-arthritic activity of a lipophilic woad (Isatis tinctoria) extract. Planta Med. 2006, 72:715-720.
9. Rüster G.U., Hoffmann B., Hamburger M. Inhibitory activity of indolin-2-one derivatives on compound 48/80-induced histamine release from mast cells. Pharmazie 2004, 59:236-237.
10. Hamburger M., Rüster G.U., Melzig M.F. HPLC based activity profiling for inhibitors of human neutrophil elastase in Isatis tinctoria leaf extracts. Nat. Prod. Commun. 2006, 1:1107-1110.
11. Kunikata T., Tatefuji T., Aga H., Iwaki K., Ikeda M., Kurimoto M. Indirubin inhibits inflammatory reactions in delayed-type hypersensitivity. Eur. J. Pharmacol. 2000, 410:93-100.
12. Ishihara T., Kohno K., Ushio S., Iwaki K., Ikeda M., Kurimoto M. Tryptanthrin inhibits nitric oxide and prostaglandin E2 synthesis by murine macrophages. Eur. J. Pharmacol. 2000, 407:197-204.
13. Oberthür C., Heinemann C., Elsner P., Benfeldt E., Hamburger M. A comparative study on the skin penetration of pure tryptanthrin and tryptanthrin in Isatis tinctoria extract by dermal microdialysis coupled with isotope dilution ESI-LC-MS. Planta Med. 2003, 69:385-389.
14. Oberthür C., Jäggi R., Hamburger M. HPLC based activity profiling for 5-lipoxygenase inhibitory activity in Isatis tinctoria leaf extracts. Fitoterapia 2005, 76:324-332.
15. Danz H., Baumann D., Hamburger M. Quantitative determination of the dual COX-2/5-LOX inhibitor tryptanthrin in Isatis tinctoria by ESI-LC-MS. Planta Med. 2002, 68:152-157.
16. Danz H., Stoyanova S., Thomet O.A.R., Simon H.-U., Dannhardt G., Ulbrich H., et al. Inhibitory activity of tryptanthrin on prostaglandin and leukotriene synthesis. Planta Med. 2002, 68:875-880.
17. Danz H., Stoyanova S., Wippich P., Brattström A., Hamburger M. Identification and isolation of the cyclooxygenase-2 inhibitory principle in Isatis tinctoria. Planta Med. 2001, 67:411-416.
18. Mohn T., Plitzko I., Hamburger M. A comprehensive metabolite profiling of Isatis tinctoria leaf extracts. Phytochemistry 2009, 70:924-934.
19. Leclerc S., Garnier M., Hoessel R., Marko D., Bibb J.A., Snyder G.L., et al. Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J. Biol. Chem. 2001, 276:251-260.
20. Heinemann C., Schliemann-Willers S., Oberthür C., Hamburger M., Elsner P. Prevention of experimentally induced irritant contact dermatitis by extracts of Isatis tinctoria compared to pure tryptanthrin and its impact on UVB-induced erythema. Planta Med. 2004, 70:385-390.
21. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
22. Oufir M., Sampath C., Butterweck V., Hamburger M. Development and full validation of an UPLC-MS/MS method for the determination of an anti-allergic indolinone derivative in rat plasma, and application to a preliminary pharmacokinetic study. J. Chromatogr. B 2012, 902:27-34.
23. Doan K.M.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303:1029-1037.
24. Kikuchi R., de Morais S.M., Kalvass J.C. In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class. Drug Metab. Dispos. 2013, 41:2012-2017.
25. Eigenmann D.E., Xue G., Kim K.S., Moses A.V., Hamburger M., Oufir M. Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 2013, 10:33.
26. Cecchelli R., Dehouck B., Descamps L., Fenart L., Buée-Scherrer V., Duhem C., et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 1999, 36:165-178.
27. Nakagawa S., Deli M.A., Kawaguchi H., Shimizudani T., Shimono T., Kittel A., et al. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 2009, 54:253-263.
28. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem. 1998, 41:2588-2603.
29. Mohn T., Potterat O., Hamburger M. Quantification of active principles and pigments in leaf extracts of Isatis tinctoria by HPLC/UV/MS. Planta Med. 2007, 73:151-156.
30. Stins M.F., Badger J., Sik Kim K. Bacterial invasion and transcytosis in transfected human brain microvascular endothelial cells. Microb. Pathog. 2001, 30:19-28.
31. Wegener J., Abrams D., Willenbrink W., Galla H.-J., Janshoff A. Automated multi-well device to measure transepithelial electrical resistances under physiological conditions. Biotechniques 2004, 37:590.
32. Dehouck M.-P., Méresse S., Delorme P., Fruchart J.-C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J. Neurochem. 1990, 54:1798-1801.
33. Booher J., Sensenbrenner M. Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 1972, 2:97.
34. Boveri M., Berezowski V., Price A., Slupek S., Lenfant A.-M., Benaud C., et al. Induction of blood-brain barrier properties in cultured brain capillary endothelial cells: comparison between primary glial cells and C6 cell line. Glia 2005, 51:187-198.
35. Veszelka S., Pásztói M., Farkas A.E., Krizbai I., Dung N.T.K., Niwa M., et al. Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem. Int. 2007, 50:219-228.
36. Veszelka S., Tóth A.E., Walter F.R., Datki Z., Mózes E., Fülöp L., et al. Docosahexaenoic acid reduces amyloid-b induced toxicity in cells of the neurovascular unit. J. Alzheimers Dis. 2013, 36:487-501.
37. Perriere N., Demeuse P.H., Garcia E., Regina A., Debray M., Andreux J.-P., et al. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J. Neurochem. 2005, 93:279-289.
38. Nakagawa S., Deli M.A., Nakao S., Honda M., Hayashi K., Nakaoke R., et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 2007, 27:687-694.
39. Deli M.A., Ábrahám C.S., Kataoka Y., Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell. Mol. Neurobiol. 2005, 25:59-127.
40. Youdim K.A., Avdeef A., Abbott N.J. In vitro trans-monolayer permeability calculations: often forgotten assumptions. Drug Discovery Today 2003, 8:997-1003.
41. Kerns E., Di L. Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization 2008, Academic Press.
42. Sjöstedt N., Kortejärvi H., Kidron H., Vellonen K.-S., Urtti A., Yliperttula M. Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier. Pharm. Res. 2014, 31:1-19.
43. Uchida Y., Ohtsuki S., Katsukura Y., Ikeda C., Suzuki T., Kamiie J., et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem. 2011, 117:333-345.
44. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 2001, 299:620-628.
45. Giacomini K.M., Huang S.-M., Tweedie D.J., Benet L.Z., Brouwer K.L., Chu X., et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 2010, 9:215-236.
46. Bauer B., Miller D.S., Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm. Res. 2003, 20:1170-1176.
47. Ott M., Huls M., Cornelius M.G., Fricker G. St John's wort constituents modulate P-glycoprotein transport activity at the blood-brain barrier. Pharm. Res. 2010, 27:811-822.
48. Veber D.F., Johnson S.R., Cheng H.-Y., Smith B.R., Ward K.W., Kopple K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002, 45:2615-2623.
49. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 1998, 6:151-165.
50. Hubatsch I., Ragnarsson E.G., Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2007, 2:2111-2119.
51. Gaillard P.J., de Boer A.G. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur. J. Pharm. Sci. 2000, 12:95-102.